The protective effect of rivaroxaban against stroke in people with cardiovascular disease greatly outweighs the bleeding risk, especially in high-risk patients, a new analysis of the landmark COMPASS study shows. In 2017 the rivaroxaban trial in people with stable cardiovascular disease was stopped early because of “overwhelming efficacy” in reducing the risk of stroke, myocardial ...
DOAC stroke protection greatly outweighs bleeding risk
By Michael Woodhead
27 May 2020